Optimizing Medical Affairs’ Role in Hematology Launches

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Medical Affairs Product Launch in Hematology: Roles, Collaboration, and Evolution”

STUDY OVERVIEW

The intricacies of hematology product launches demand that Medical Affairs continually redefine their roles and collaborative efforts to navigate the unique challenges of this therapeutic area. Their strategic involvement is key to ensuring that new treatments effectively reach the patients who need them most.

Best Practices, LLC's benchmarking research investigates how Medical Affairs groups can adapt to the evolving landscape in hematology product launches. This study provides insights into leadership roles, evolving responsibilities, effective cross-functional collaboration, and the ongoing transformation within the field of hematology.

KEY TOPICS

Medical Leadership Roles and Launch Activity Effectiveness in Hematology
Ensuring Cross-functional Alignment and Collaboration in Hematology Launches
Adopting to Ongoing Changes in Medical Landscape

KEY METRICS

Medical Affairs’ leadership role in hematology launches
Optimizing Medical Affairs launch activities in hematology
Improvement areas for Medical Affairs around hematology launches
Medical Affairs’ internal collaboration for hematology launch success
Medical Affairs’ cross-functional team role in hematology product launches

SAMPLE KEY FINDINGS

Medical Leadership Roles: The top quartile of 26 high-value activities in hematology includes planning advisory boards, training internally on disease state, developing medical strategy, conducting medical education and ensuring medical communication execution.

METHODOLOGY

This benchmarking study engaged 17 Medical leaders from 14 leading life sciences organizations. The study insights are drawn primarily from Medical Directors and upper management executives, representing nearly 80% of the benchmark class.

Industries Profiled:
Biopharmaceutical; Pharmaceutical; Academic; Research; Biotech; Chemical; Consulting; Consumer Products; Health Care; Medical Device

Companies Profiled:
Apellis Pharmaceuticals; ASC Therapeutics; AstraZeneca; Duke University and Health System; Eurofarma; Genentech; Helsinn; Kyowa Kirin; MEDiSTRAVA; Novartis; Pixacore; Sandoz; Takeda Pharmaceuticals; Terumo BCT: Terumo Blood and Cell Technologies

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Medical Affairs Product Launch in Hematology: Roles, Collaboration, and Evolution

ID: 5821

Features:

Pages/Slides: 31

Published: 2024

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63268B4433A0D537500258B880038935D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-product-launch-in-hematology-roles-collaboration-evolution?opendocument
18
19opendocument
203.238.82.77
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB